<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="mco270218" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">MedComm (2020)</journal-id><journal-id journal-id-type="iso-abbrev">MedComm (2020)</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2688-2663</journal-id><journal-id journal-id-type="publisher-id">MCO2</journal-id><journal-title-group><journal-title>MedComm</journal-title></journal-title-group><issn pub-type="epub">2688-2663</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12099067</article-id><article-id pub-id-type="doi">10.1002/mco2.70218</article-id><article-id pub-id-type="publisher-id">MCO270218</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Long Noncoding RNA LINC02820 Promotes Tumor Growth and Metastasis Through Regulating MYH9 Expression in Esophageal Squamous Cell Carcinoma</article-title></title-group><contrib-group><contrib id="mco270218-cr-0001" contrib-type="author"><name><surname>Xu</surname><given-names>Xiaomin</given-names></name><xref rid="mco270218-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270218-cr-0002" contrib-type="author"><name><surname>Mao</surname><given-names>Xinting</given-names></name><xref rid="mco270218-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270218-cr-0003" contrib-type="author"><name><surname>Liu</surname><given-names>Wenrong</given-names></name><xref rid="mco270218-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270218-cr-0004" contrib-type="author"><name><surname>Ming</surname><given-names>Yue</given-names></name><xref rid="mco270218-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270218-cr-0005" contrib-type="author"><name><surname>Zhang</surname><given-names>Tingting</given-names></name><xref rid="mco270218-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270218-cr-0006" contrib-type="author"><name><surname>Yang</surname><given-names>Yang</given-names></name><xref rid="mco270218-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="mco270218-cr-0007" contrib-type="author"><name><surname>Gu&#x02010;Ha</surname><given-names>A&#x02010;Lai</given-names></name><xref rid="mco270218-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="mco270218-cr-0008" contrib-type="author" corresp="yes"><name><surname>Lin</surname><given-names>Yi&#x02010;Dan</given-names></name><xref rid="mco270218-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>linyidan.academy@foxmail.com</email></address></contrib><contrib id="mco270218-cr-0009" contrib-type="author" corresp="yes"><name><surname>Peng</surname><given-names>Yong</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1181-3467</contrib-id><xref rid="mco270218-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>yongpeng@scu.edu.cn</email></address></contrib></contrib-group><aff id="mco270218-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Center for Molecular Oncology</named-content>
<named-content content-type="organisation-division">Frontiers Science Center for Disease&#x02010;Related Molecular Network</named-content>
<named-content content-type="organisation-division">State Key Laboratory of Biotherapy and Cancer Center</named-content>
<institution>West China Hospital</institution>
<institution>Sichuan University</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="mco270218-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Thoracic Surgery</named-content>
<institution>West China Hospital</institution>
<institution>Sichuan University</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>6</volume><issue seq="110">6</issue><issue-id pub-id-type="doi">10.1002/mco2.v6.6</issue-id><elocation-id>e70218</elocation-id><history>
<date date-type="rev-recd"><day>12</day><month>4</month><year>2025</year></date>
<date date-type="received"><day>14</day><month>4</month><year>2024</year></date>
<date date-type="accepted"><day>16</day><month>4</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">MedComm</italic> published by Sichuan International Medical Exchange &#x00026; Promotion Association (SCIMEA) and John Wiley &#x00026; Sons Australia, Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:MCO2-6-e70218.pdf"/><abstract><title>Abstract</title><p>Long noncoding RNAs (lncRNAs) play important roles in tumorigenesis, but their biological functions and mechanisms in esophageal squamous cell carcinoma (ESCC) remain poorly understood. In this study, we employed high&#x02010;throughput sequencing and bioinformatics analyses to identify the differentially expressed lncRNAs between ESCC tumors and adjacent normal tissues, among which LINC02820 is significantly upregulated in ESCC. Rapid amplification of cDNA ends assays determined the transcription initiation and termination sites of LINC02820, confirming it as a novel transcript variant localized in both the nucleus and cytoplasm of ESCC cells. Functional studies demonstrated that LINC02820 promotes cell proliferation and migration in vitro and enhances tumor growth and metastasis in vivo. Mechanistically, LINC02820 interacts with Myosin&#x02010;9 protein and prevent it from ubiquitination&#x02010;mediated proteasomal degradation. Additionally, the RNA&#x02010;binding protein insulin&#x02010;like growth factor 2 mRNA&#x02010;binding protein 2 binds to LINC02820 and increase its RNA stability in ESCC cells, thus upregulating LINC02820 expression. Therefore, these findings indicate LINC02820 as an oncogenic lncRNA in ESCC progression and suggest its potential as a therapeutic target.</p></abstract><abstract id="mco270218-abs-0001" abstract-type="graphical"><p>This study demonstrates that the RNA&#x02010;binding protein IGF2BP2 binds to and stabilizes LINC02820, leading to elevated LINC02820 expression in esophageal squamous cell carcinoma (ESCC). Moreover, association of LINC02820 with MYH9 protein protects MYH9 from proteasomal degradation, thus upregulating MYH9 to promote tumor growth and metastasis in ESCC.
<boxed-text position="anchor" content-type="graphic"><graphic xlink:href="MCO2-6-e70218-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="mco270218-kwd-0001">esophageal squamous cell carcinoma</kwd><kwd id="mco270218-kwd-0002">LINC02820</kwd><kwd id="mco270218-kwd-0003">MYH9</kwd><kwd id="mco270218-kwd-0004">IGF2BP2</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>the 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University</funding-source><award-id>ZYGD23027</award-id></award-group></funding-group><counts><fig-count count="7"/><table-count count="0"/><page-count count="14"/><word-count count="7440"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="mco270218-note-0001" fn-type="equal"><p>Xiaomin Xu and Xinting Mao&#x000a0;contributed equally to this work.</p></fn><fn id="mco270218-note-0002"><p>
<bold>Funding</bold>: the 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University (ZYGD23027).</p></fn></fn-group></notes></front><body><sec id="mco270218-sec-0010"><label>1</label><title>Introduction</title><p>Esophageal cancer (ESCA), a highly prevalent digestive tract malignancy, is histologically categorized into two main subtypes: esophageal adenocarcinoma and esophageal squamous cell carcinoma (ESCC) [<xref rid="mco270218-bib-0001" ref-type="bibr">1</xref>]. In China, the majority of ESCA cases are diagnosed at late&#x02010;stage ESCC due to the lack of early symptomatic presentation, contributing to its high mortality rate. Despite advances in treatment strategies, such as surgery and chemotherapy, the 5&#x02010;year survival rate for ESCC patients remains unsatisfactory [<xref rid="mco270218-bib-0002" ref-type="bibr">2</xref>, <xref rid="mco270218-bib-0003" ref-type="bibr">3</xref>]. These clinical challenges underscore the urgent need to decipher the molecular mechanisms driving ESCC tumorigenesis and development.</p><p>Long noncoding RNAs (lncRNAs) are a class of RNA transcripts&#x000a0;&#x0003e;&#x000a0;200 nucleotides generally lacking protein&#x02010;coding potential. Accumulating evidence indicates that lncRNAs perform important regulatory functions at transcriptional, posttranscriptional, and translational levels under physiological conditions [<xref rid="mco270218-bib-0004" ref-type="bibr">4</xref>, <xref rid="mco270218-bib-0005" ref-type="bibr">5</xref>]. Their abnormal expression can disrupt key biological processes and contribute to disease pathogenesis, including cancer [<xref rid="mco270218-bib-0006" ref-type="bibr">6</xref>, <xref rid="mco270218-bib-0007" ref-type="bibr">7</xref>, <xref rid="mco270218-bib-0008" ref-type="bibr">8</xref>]. For examples, the ultra&#x02010;conserved lncRNA THOR exhibits an elevated expression in multiple cancers and promotes tumor growth by enhancing cell proliferation [<xref rid="mco270218-bib-0009" ref-type="bibr">9</xref>] and the lncRNA H19 shows a remarkably increased expression in bladder cancer and is implicated in metastasis through modulating epithelial&#x02013;mesenchymal transition [<xref rid="mco270218-bib-0010" ref-type="bibr">10</xref>]. Recent studies have revealed widespread dysregulation of lncRNA expression in ESCC [<xref rid="mco270218-bib-0011" ref-type="bibr">11</xref>]. To date, only a limited number of lncRNAs have been functionally characterized, exhibiting diverse regulatory roles in ESCC progression. For instance, super&#x02010;enhancer&#x02010;driven overexpression of LINC01503 promotes ESCC cell proliferation, migration, and invasion via activating ERK signaling [<xref rid="mco270218-bib-0012" ref-type="bibr">12</xref>]. Both LINC00680 and LINC00022 can enhance tumor growth, correlating with poor prognosis [<xref rid="mco270218-bib-0013" ref-type="bibr">13</xref>, <xref rid="mco270218-bib-0014" ref-type="bibr">14</xref>]. Additionally, lncRNAs such as SLC25A21&#x02010;AS1 and NORAD regulate critical oncogenic pathways, including the NPM1/c&#x02010;Myc and miR&#x02010;224&#x02010;3p/MTDH axes, thereby modulating tumor aggressiveness and chemoresistance in ESCC [<xref rid="mco270218-bib-0015" ref-type="bibr">15</xref>, <xref rid="mco270218-bib-0016" ref-type="bibr">16</xref>]. Besides, the upregulation of the lncRNA AGPG activates glycolytic flux and accelerates cell cycle progression in ESCC [<xref rid="mco270218-bib-0017" ref-type="bibr">17</xref>]. Despite these advances, the biological roles of most lncRNAs in ESCC remain unexplored, warranting further investigations.</p><p>LncRNAs regulate gene expression through interactions with DNA, RNA, or RNA&#x02010;binding protein (RBP), thereby influencing key hallmarks of caner [<xref rid="mco270218-bib-0004" ref-type="bibr">4</xref>, <xref rid="mco270218-bib-0018" ref-type="bibr">18</xref>]. For examples, the lncRNA MEG3 regulates the TGF&#x02010;&#x003b2; pathway genes through formation of RNA&#x02013;DNA triplex structures [<xref rid="mco270218-bib-0019" ref-type="bibr">19</xref>], while H19 acts as a molecular sponge for miR&#x02010;675 to regulate cell proliferation [<xref rid="mco270218-bib-0020" ref-type="bibr">20</xref>]. LncRNA&#x02013;protein interaction is a more commonly observed mechanism, which modulates protein function or regulates protein&#x02013;protein interaction. For instance, the p53&#x02010;induced lncRNA&#x02013;p21 mediates global gene repression during the p53 response by its physical association with hnRNP K [<xref rid="mco270218-bib-0021" ref-type="bibr">21</xref>]. Similarly, the lncRNA BREA2 stabilizes NICD1 by impairing the complex formation of NICD1 protein and the E3 ligase WWP2, leading to Notch signaling activation and lung metastasis [<xref rid="mco270218-bib-0022" ref-type="bibr">22</xref>]. On the other hand, lncRNA&#x02013;RBP complex may affect lncRNA abundance. In gallbladder cancer, the RBP HuR stabilizes the lncRNA&#x02013;HGBC, enhancing its oncogenic function and promoting metastasis [<xref rid="mco270218-bib-0023" ref-type="bibr">23</xref>]. Therefore, understanding how lncRNA&#x02013;protein complex regulate ESCC development may facilitate the identification of novel therapeutic targets.</p><p>In this study, we identified significant upregulation of LINC02820 in ESCC tumors. Mechanistically, we found that insulin&#x02010;like growth factor 2 mRNA&#x02010;binding protein 2 (IGF2BP2) binds to and stabilizes LINC02820, leading to its elevated expression in ESCC cells. Functional assays employing both gain&#x02010; and loss&#x02010;of&#x02010;function approaches revealed that LINC02820 promotes tumor cell proliferation and migration in vitro and enhances tumor growth and metastasis in vivo. Further mechanistic investigation demonstrated that LINC02820 interacts with MYH9 protein and protects it from ubiquitination&#x02013;proteasomal degradation. Therefore, our findings identify the oncogenic functions of LINC02820 in ESCC progression and underscore its potential as a therapeutic target.</p></sec><sec id="mco270218-sec-0020"><label>2</label><title>Results</title><sec id="mco270218-sec-0030"><label>2.1</label><title>LINC02820 Expression is Upregulated in ESCC</title><p>To identify differentially expressed lncRNAs in ESCC, we performed Ribo&#x02010;Zero high&#x02010;throughput RNA&#x02010;Sequencing followed by comprehensive bioinformatics analysis. The results revealed 91 upregulated and 60 downregulated lncRNAs in ESCC tumor tissues compared with normal controls (Figure&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1A,B</xref> and Table <xref rid="mco270218-supinfo-0001" ref-type="">S1</xref>). Notably, LINC02820 exhibited an 8.5&#x02010;fold increase in ESCC tumors, while C5orf66&#x02010;AS1 and AC004816.1 showed significant downregulation (Figures&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1C</xref> and <xref rid="mco270218-supinfo-0001" ref-type="">S1A</xref>). To verify our RNA&#x02010;Sequencing results, we compared our data with another ESCC cohort of HRA003107 data and observed that approximately 62% of differentially expressed lncRNAs we identified overlapped with the HRA003107 data (Figure&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1D</xref>). Next, we collected independent set of paired ESCC samples to measure lncRNA levels by real&#x02010;time quantitative polymerase chain reaction (RT&#x02010;qPCR), and the results showed that most of tested lncRNAs exhibited consistent expression patterns with our sequencing data (Figures&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1E</xref> and <xref rid="mco270218-supinfo-0001" ref-type="">S1B</xref>). Moreover, bioinformatics analyses from The Cancer Genome Atlas (TCGA) and GSE130078 datasets confirmed that LINC02820 was dramatically upregulated in ESCC tissues (Figure&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1F,G</xref>), suggesting its potential oncogenic role. Subsequently, we performed gene set enrichment analysis (GSEA) to explore biological processes and signaling pathways regulated by LINC02820. The results showed that higher LINC02820 expression is significantly enriched in cell cycle regulation and metastasis&#x02010;related pathways in ESCA (Figure&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1H,I</xref>), suggesting its functional involvement in ESCA cell proliferation and migration.</p><fig position="float" fig-type="FIGURE" id="mco270218-fig-0001"><label>FIGURE 1</label><caption><p>LINC02820 expression is upregulated in ESCC. (A) Volcano plot and (B) hierarchical cluster plot exhibiting differentially expressed lncRNAs between ESCC tumors and paired corresponding normal tissues from our Ribo&#x02010;Zero RNA&#x02010;seq data. (C) LINC02820 expression in ESCC tumors and paired normal tissues from our RNA&#x02010;Seq data. (D) Venn diagrams showing the overlap of differentially expressed lncRNAs (gene&#x02010;level) between our ESCC RNA&#x02010;seq data (118 genes from 151 transcripts) and the HRA003107 dataset (2103 genes). (E) RT&#x02010;qPCR analysis of LINC02820 expression in ESCC tumors and adjacent normal tissues from 6 patients. LINC02820 levels were normalized to <italic toggle="yes">ACTB</italic> mRNAs. (F and G) LINC02820 expression between ESCC tumors and normal tissues in TCGA&#x02013;ESCC (F) and GSE130078 (G) datasets. (H and I) Gene Set Enrichment Analysis showing the association of LINC02820 abundance with cell cycle (H) and metastasis (I) pathways in the TCGA dataset.</p></caption><graphic xlink:href="MCO2-6-e70218-g001" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="mco270218-sec-0040"><label>2.2</label><title>Characterization and Subcellular Distribution of LINC02820 in ESCC Cells</title><p>Analysis of our high&#x02010;throughput RNA&#x02010;Seq data revealed that LINC02820 consists of three exons and exhibited extended read lengths compared with the reference sequence (ENST00000555596) in the Ensembl database (Figure&#x000a0;<xref rid="mco270218-fig-0002" ref-type="fig">2A</xref>). To experimentally validate the transcription initiation and termination sites of LINC02820, we performed 5&#x02032; and 3&#x02032; rapid amplification of cDNA ends (RACE), followed by Sanger sequencing. Both RACE assays yielded single distinct bands, with sequencing results identifying 16 additional nucleotides at the 5&#x02032; end and 118 extra nucleotides at the 3&#x02032; end that were absent in the database annotation (Figure&#x000a0;<xref rid="mco270218-fig-0002" ref-type="fig">2B,C</xref>). Subsequent amplification and sequencing of the full&#x02010;length transcript confirmed LINC02820 as a 653&#x02010;nucleotide RNA (Figures&#x000a0;<xref rid="mco270218-fig-0002" ref-type="fig">2D</xref> and <xref rid="mco270218-supinfo-0001" ref-type="">S2</xref>). Consistent with its classification as a lncRNA, bioinformatics analysis using the Coding Potential Calculator (<ext-link xlink:href="http://cpc.cbi" ext-link-type="uri">http://cpc.cbi</ext-link>. pku.edu.cn/) confirmed that LINC02820 lacks protein&#x02010;encoding capacity.</p><fig position="float" fig-type="FIGURE" id="mco270218-fig-0002"><label>FIGURE 2</label><caption><p>Characterization and subcellular distribution of LINC02820 in ESCC cells. (A) Identification of LINC02820 variant in ESCC tumors. Upper panel, the genomic loci of LINC02820; middle panel, our high&#x02010;throughput RNA&#x02010;Seq profiles in LINC02820 loci; lower panel, schematic diagram of ENST00000555596. (B and C) Agarose gel electrophoresis of PCR products generated by 5&#x02032;&#x02010;RACE (B) and 3&#x02032;&#x02010;RACE (C), Sanger sequencing confirms extra nucleotides of LINC02820 variant. (D) Agarose gel electrophoresis of the full&#x02010;length LINC02820 variant generated by RT&#x02010;PCR. (E) RT&#x02010;qPCR measurement of LINC02820 levels in ESCC cells. LINC02820 expression is normalized to <italic toggle="yes">ACTB</italic> mRNAs. (F and G) Subcellular distribution of LINC02820 in KYSE30 (F) and KYSE410 (G) cells determined by RT&#x02010;qPCR assay. Western blot assays with GAPDH and Lamin A/C antibodies confirm effective cytoplasmic/nuclear fractionation. <italic toggle="yes">GAPDH</italic> mRNA and <italic toggle="yes">U6</italic> RNA transcripts are used as the cytoplasmic and nucleus indicators, respectively.</p></caption><graphic xlink:href="MCO2-6-e70218-g007" position="anchor" id="jats-graphic-5"/></fig><p>To investigate the functional role of LINC02820 in ESCC, we first examined its expression patterns across a panel of human ESCC cell lines. As shown in Figure&#x000a0;<xref rid="mco270218-fig-0002" ref-type="fig">2E</xref>, LINC02820 were highly expressed in KYSE30, KYSE410, and KYSE450 cells, while it exhibited lower expression in Eca109 and TE1 cells.</p><p>To determine the subcellular localization of LINC02820, we prepared cytoplasmic and nuclear fractions of KYSE410 and KYSE30 cells to measure LINC02820 levels. Western blot analysis confirmed effective separation of cytoplasmic and nuclear fractions. Subsequent RT&#x02010;qPCR analysis showed that LINC02820 is distributed in both cellular compartments (Figure&#x000a0;<xref rid="mco270218-fig-0002" ref-type="fig">2F,G</xref>), implying its potential involvement in both transcriptional and posttranscriptional regulatory mechanisms during ESCC progression.</p></sec><sec id="mco270218-sec-0050"><label>2.3</label><title>LINC02820 Promotes ESCC Tumor Growth and Metastasis</title><p>Given the relatively low endogenous expression of LINC02820 in Eca109 and TE1 cells (Figure&#x000a0;<xref rid="mco270218-fig-0002" ref-type="fig">2E</xref>), we selected these cells to successfully establish stable LINC02820&#x02010;overexpressing cells via lentiviral transduction, as evidenced by RT&#x02010;PCR analyses (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3A</xref>). Functional studies showed that ectopically expressed LINC02820 significantly enhanced cell proliferative capacity in both Eca109 and TE1 cells, as demonstrated by both MTT assays (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3B,C</xref>) and colony formation experiments (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3D</xref>). Furthermore, Transwell assays indicated that LINC02820 overexpression markedly promoted cell migration and invasion in both cell lines (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3E,F</xref>). Together, these results demonstrate that LINC02820 enhances cell proliferation, migration, and invasion abilities of ESCC cells.</p><fig position="float" fig-type="FIGURE" id="mco270218-fig-0003"><label>FIGURE 3</label><caption><p>LINC02820 promotes tumor growth and metastasis. (A) Semi&#x02010;quantitative RT&#x02010;PCR and agarose gel electrophoresis show successful LINC02820 overexpression in Eca109 and TE1 cells. (B and C) MTT assays indicate that LINC02820 overexpression promotes cell growth in Eca109 (B) and TE1 (C) cells. Data are shown as mean&#x000a0;&#x000b1;&#x000a0;s.d. <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;4. (D) Colony formation assays of ESCC cells with or without LINC02820 overexpression. (E and F) Representative Transwell migration (E) and invasion (F) images of ESCC cells with or without LINC02820 overexpression. (G&#x02013;I) LINC02820 overexpression enhances ESCC tumor growth (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;8/group). Tumors (H) and their weights (I) are displayed at the end point. (J and K) Representative bioluminescence images (J) of nude mice after tail&#x02010;vein injection with Eca109 stable cells with or without LINC02820 overexpression (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;7/group), and their bioluminescence intensities in the lungs are quantified (K).</p></caption><graphic xlink:href="MCO2-6-e70218-g003" position="anchor" id="jats-graphic-7"/></fig><p>To evaluate the effects of LINC02820 in vivo, we performed subcutaneous xenograft assays using LINC02820&#x02010;overexpressing Eca109 cells in BALB/c nude mice. Tumors derived from LINC02820&#x02010;overexpressing cells exhibited significantly increased growth rates (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3G,H</xref>) and final tumor weights (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3I</xref>) compared with control groups. Furthermore, tail&#x02010;vein injection experiments indicated that LINC02820 overexpression substantially enhanced the metastatic potential of ESCC cells, resulting in significantly more lung metastasis (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3J,K</xref>). These in vivo data collectively demonstrate that LINC02820 promotes both tumor growth and distant metastasis, supporting its oncogenic role in ESCC progression.</p></sec><sec id="mco270218-sec-0060"><label>2.4</label><title>Targeting LINC02820 Expression Inhibits ESCC Tumor Growth and Metastasis</title><p>To further validate the biological function of LINC02820 in ESCC progression, we generated stable knockdown cell lines using two independent short&#x02010;hairpin RNAs targeting LINC02820 in KYSE30 and KYSE410 cells. Quantitative RT&#x02010;PCR analysis confirmed shRNAs can efficiently knock down LINC02820 expression in both cell lines (Figure&#x000a0;<xref rid="mco270218-fig-0004" ref-type="fig">4A</xref>). Next, MTT assays showed that LINC02820 depletion significantly inhibited cell proliferation (Figure&#x000a0;<xref rid="mco270218-fig-0004" ref-type="fig">4B,C</xref>), which was further validated by colony formation experiments (Figure&#x000a0;<xref rid="mco270218-fig-0004" ref-type="fig">4D</xref>). Furthermore, Transwell assays demonstrated that LINC02820 silencing markedly reduced cell migration and invasion ability (Figure&#x000a0;<xref rid="mco270218-fig-0004" ref-type="fig">4E,F</xref>).</p><fig position="float" fig-type="FIGURE" id="mco270218-fig-0004"><label>FIGURE 4</label><caption><p>Targeting LINC0282 expression inhibits ESCC tumor growth and metastasis. (A) RT&#x02010;qPCR assays showing efficient LINC02820 knockdown by shNRAs in ESCC cells. LINC02820 expression is normalized to <italic toggle="yes">GAPDH</italic> mRNAs. (B, C) MTT assays show that LINC02820 depletion inhibits cell growth in KYSE30 (B) and KYSE410 cells (C). Data are shown as mean&#x000a0;&#x000b1;&#x000a0;s.d. <italic toggle="yes">n</italic>&#x000a0;=&#x000a0;4. (D) Colony formation assays of ESCC cells with or without LINC02820 knockdown. (E and F) Representative Transwell migration (E) and invasion (F) images of ESCC cells with or without LINC02820 knockdown. (G&#x02013;I) LINC02820 depletion represses ESCC tumor growth (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;8/group). Tumors (H) and their weights (I) are displayed at the end point. (J and K) Representative bioluminescence images of nude mice after tail&#x02010;vein injection with KYSE410 stable cells with or without LINC02820 knockdown (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;7/group), and their bioluminescence intensities in the lungs are quantified (K).</p></caption><graphic xlink:href="MCO2-6-e70218-g005" position="anchor" id="jats-graphic-9"/></fig><p>To validate the tumor&#x02010;promoting function of LINC02820 in vivo, we established xenograft models using LINC02820&#x02010;knockdown KYSE410 cells. Compared with control (shCTRL) groups, LINC02820 depletion (shLINC) significantly inhibited tumor growth (Figure&#x000a0;<xref rid="mco270218-fig-0004" ref-type="fig">4G,H</xref>) and reduced final tumor weights (Figure&#x000a0;<xref rid="mco270218-fig-0004" ref-type="fig">4I</xref>). Moreover, tail&#x02010;vein injection experiments of KYSE410 stable cells indicated that LINC02820 silencing substantially diminished lung metastatic colonization (Figure&#x000a0;<xref rid="mco270218-fig-0004" ref-type="fig">4J,K</xref>). Together with our overexpression results (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3</xref>), these gain&#x02010; and loss&#x02010;of&#x02010;function studies support the essential role of LINC02820 in promoting ESCC tumor growth and metastasis.</p></sec><sec id="mco270218-sec-0070"><label>2.5</label><title>IGF2BP2 Enhances LINC02820 Stability in ESCC Cells</title><p>Accumulating evidence demonstrates that lncRNAs functionally interact with RBPs to regulate gene expression or to be regulated by proteins. To identify LINC02820&#x02010;associating proteins in ESCC, we performed RNA pull&#x02010;down assays using in vitro transcribed sense or antisense LINC02820, Coomassie blue staining revealed several proteins (&#x0003e;180, &#x0003e;70, and &#x0003e;55&#x000a0;kDa) specifically enriched by biotinylated LINC02820 from both KYSE410 (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5A</xref>) and KYSE30 cell lysates (Figure <xref rid="mco270218-supinfo-0001" ref-type="">S3A</xref>), which were subsequently excised for mass spectrometry analyses (Tables <xref rid="mco270218-supinfo-0001" ref-type="">S2&#x02013;S4</xref>). Moreover, we analyzed CLIP&#x02010;seq data from starBase v2.0 and identified 12 potential LINC02820&#x02010;interacting RBPs (Table <xref rid="mco270218-supinfo-0001" ref-type="">S5</xref>). Notably, IGF2BP2 was identified by both our mass spectrometry data and CLIP&#x02010;seq analyses (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5B,C</xref>), supporting it as a binding partner of LINC02820. Next, we validated this interaction through independent RNA pull&#x02010;down assays followed by immunoblotting, which confirmed specific association between IGF2BP2 and LINC02820 (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5D</xref>). Furthermore, reciprocal RBP immunoprecipitation using anti&#x02010;IGF2BP2 antibody also revealed significant enrichment of LINC02820 in the immunoprecipitated fraction compared with controls (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5E</xref>). Together, these results demonstrate that IGF2BP2 binds to LINC02820 in ESCC cells.</p><fig position="float" fig-type="FIGURE" id="mco270218-fig-0005"><label>FIGURE 5</label><caption><p>IGF2BP2 enhances LINC02820 stability in ESCC cells. (A) Coomassie blue staining of LINC02820&#x02010;interacting proteins pulled down by the biotinylated LINC02820 or antisense transcripts from KYSE410 cell extracts. Proteins indicated by red numbers were subjected to mass spectrometry analysis. (B) Venn diagrams showing the overlap of LINC02820&#x02010;associated proteins between our mass spectrometry data and CLIP&#x02010;seq dataset. (C) A representative IGF2BP2 peptide identified by LC&#x02013;MS/MS. (D) Immunoblot assays show that IGF2BP2 was specifically pulled down by the biotinylated LINC02820 from KYSE30 or KYSE410 cell extracts. (E) RIP assays with anti&#x02010;IGF2BP2 antibody indicate the association of LINC02820 with IGF2BP2 in KYSE30 or KYSE410 cells. (F) Immunoblot assays show efficient IGF2BP2 knockdown by shRNAs in KYSE30 and KYSE410 cells. (G) RT&#x02010;qPCR analyses of LINC02820 levels in ESCC cells treated with actinomycin D for indicated times. (H) RT&#x02010;qPCR analyses show steady&#x02010;state levels of LINC02820 in control and IGF2BP2&#x02010;depletion ESCC cells. LINC02820 expression is normalized to <italic toggle="yes">GAPDH</italic> mRNA. (I) <italic toggle="yes">IGF2BP2</italic> mRNA levels between ESCC tumors and paired normal tissues in our RNA&#x02010;Seq data. (J and K) <italic toggle="yes">IGF2BP2</italic> mRNA expression between tumors and normal tissues in TCGA&#x02013;ESCA (J) and GSE130078 (K) datasets. (L) Kaplan&#x02013;Meier survival curves of individuals with <italic toggle="yes">IGF2BP2</italic> mRNA expression in the TCGA dataset.</p></caption><graphic xlink:href="MCO2-6-e70218-g004" position="anchor" id="jats-graphic-11"/></fig><p>Given the established role of IGF2BP2 protein in stabilizing target RNAs, such as <italic toggle="yes">Wnt7B</italic> mRNA and the lncRNA DANCR [<xref rid="mco270218-bib-0024" ref-type="bibr">24</xref>, <xref rid="mco270218-bib-0025" ref-type="bibr">25</xref>, <xref rid="mco270218-bib-0026" ref-type="bibr">26</xref>, <xref rid="mco270218-bib-0027" ref-type="bibr">27</xref>], we wonder if IGF2BP2 similarly regulates LINC02820 stability. To this end, we generated stable IGF2BP2&#x02010;depletion cell lines using two different shRNAs in both KYSE30 and KYSE410 cells. First, the immunoblotting results confirmed that IGF2BP2 were efficiently knocked down in both cell lines (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5F</xref>). To assess RNA stability, we treated cells with actinomycin D to block new RNA synthesis and monitored LINC02820 levels over time by RT&#x02010;qPCR. As shown in Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5G</xref>, LINC02820 exhibited significantly accelerated decay following IGF2BP2 depletion in both cell lines, indicating that IGF2BP2 enhances LINC02820 stability. Consistent with this finding, IGF2BP2 knockdown substantially reduced steady&#x02010;state LINC02820 expression levels (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5H</xref>).</p><p>To explore the clinical relevance of LINC02820 and IGF2BP2 in ESCC, we first analyzed their expression patterns in our sequencing dataset and found that IGF2BP2 expression were significantly elevated in ESCC tumors compared with paired adjacent normal tissues (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5I</xref>), which was further validated in both TCGA (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5J</xref>) and GSE130078 datasets (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5K</xref>). Notably, we observed a strong positive correlation between IGF2BP2 and LINC02820 expression levels (Figure <xref rid="mco270218-supinfo-0001" ref-type="">S3B</xref>), suggesting that IGF2BP2&#x02010;mediated regulation may contribute to LINC02820 upregulation in ESCA. Importantly, higher IGF2BP2 expression was significantly associated with worse clinical outcomes in ESCA patients (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5L</xref>), underscoring its potential prognostic value.</p><p>Considering that the lncRNA BREA2 has been shown to interact with and stabilize NICD1 protein [<xref rid="mco270218-bib-0022" ref-type="bibr">22</xref>], we sought to determine whether LINC02820 similarly regulates IGF2BP2 expression. However, neither LINC02820 knockdown nor overexpression significantly altered IGF2BP2 protein levels (Figure <xref rid="mco270218-supinfo-0001" ref-type="">S3C,D</xref>). These results indicate that while IGF2BP2 stabilizes LINC02820, this interaction does not reciprocally regulate IGF2BP2 expression in ESCC cells.</p></sec><sec id="mco270218-sec-0080"><label>2.6</label><title>LINC02820 Interacts with and Increases MYH9 Protein in ESCC Cells</title><p>Our mass spectrometry analysis identified Myosin&#x02010;9 (MYH9) as a high&#x02010;confidence LINC02820&#x02010;interacting protein, supported by robust identification metrics including a high mass spectrometry score (Sum PEP Score&#x000a0;=&#x000a0;821.942), numerous unique peptides (127), and extensive sequence coverage (50%) (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6A</xref> and Table <xref rid="mco270218-supinfo-0001" ref-type="">S2</xref>). Given MYH9's established roles in maintaining cell morphology, cell adhesion and cytokinesis [<xref rid="mco270218-bib-0028" ref-type="bibr">28</xref>], and its association with postoperative ESCC recurrence [<xref rid="mco270218-bib-0029" ref-type="bibr">29</xref>], we performed RNA pull&#x02010;down experiments and immunoblotting assays to confirm the interaction between LINC02820 and MYH9. The results showed that MYH9 protein was specifically captured from ESCC cell lysates by LINC02820, but not by antisense RNA (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6B</xref>). Furthermore, RIP assays confirmed endogenous association between LINC02820 and MYH9 in both KYSE30 and KYSE410 cells (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6C</xref>). Increasing studies report that lncRNAs can modulate protein stability [<xref rid="mco270218-bib-0030" ref-type="bibr">30</xref>, <xref rid="mco270218-bib-0031" ref-type="bibr">31</xref>], so we wonder if LINC02820 has an effect on MYH9 protein abundance. The results showed that LINC02820 depletion decreased MYH9 protein levels (Figures&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6D</xref> and <xref rid="mco270218-supinfo-0001" ref-type="">S4C</xref>), whereas LINC02820 overexpression increased MYH9 protein abundance (Figures&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6E</xref> and <xref rid="mco270218-supinfo-0001" ref-type="">S4D</xref>). Notably, neither LINC02820 knockdown or overexpression had impact on MYH9 mRNA levels (Figure <xref rid="mco270218-supinfo-0001" ref-type="">S4A,B</xref>), implying that LINC20280 regulates MYH9 expression through posttranslational mechanisms rather other transcriptional control.</p><fig position="float" fig-type="FIGURE" id="mco270218-fig-0006"><label>FIGURE 6</label><caption><p>LINC02820 interacts with and increases MYH9 protein in ESCC cells. (A) A representative MYH9 peptide identified by LC&#x02013;MS/MS. (B) Pulldown of MYH9 by the biotinylated LINC02820 from KYSE30 or KYSE410 cell extracts. (C) RIP assays using anti&#x02010;MYH9 antibody indicate the association of LINC02820 with MYH9 protein in KYSE30 and KYSE410 cells. (D and E) Effects of LINC02820 knockdown (D) and overexpression (E) on MYH9 expression in ESCC cells. (F) Effects of MG132 treatment on MYH9 protein levels in ESCC cells. (G) Immunoblot analyses of MYH9 levels in different KYSE30 cells treated with cycloheximide for indicated times. (H and I) Polyubiquitination status of MYH9 proteins immunoprecipitated from Eca109 (H) and TE1 cells (I) with or without LINC02820 overexpression.</p></caption><graphic xlink:href="MCO2-6-e70218-g006" position="anchor" id="jats-graphic-13"/></fig></sec><sec id="mco270218-sec-0090"><label>2.7</label><title>LINC02820 Protects MYH9 from Ubiquitination&#x02010;Mediated Proteasomal Degradation</title><p>Since MYH9 is known to be regulated by ubiquitin&#x02013;proteasome pathway [<xref rid="mco270218-bib-0032" ref-type="bibr">32</xref>, <xref rid="mco270218-bib-0033" ref-type="bibr">33</xref>], we first examined MYH9 protein levels after treating cells with the proteasome inhibitor MG132. As shown in Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6F</xref>, MG132 treatment effectively increased MYH9 abundance in both Eca109 and TE1 cells. To directly assess MYH9 stability, we treated cells with cycloheximide (CHX) to block protein synthesis for indicated times, and then measured MYH9 protein by immunoblotting analysis. The results showed that MYH9 protein levels declined more quickly after LINC02820 knockdown in ESCC cells (Figures&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6G</xref> and <xref rid="mco270218-supinfo-0001" ref-type="">S4E</xref>), indicating that LINC02820 prolongs the half&#x02010;life of MYH9 protein. Given the critical role of polyubiquitination in protein degradation [<xref rid="mco270218-bib-0034" ref-type="bibr">34</xref>], we next evaluated the effects of LINC02820 on MYH9 ubiquitination status. The result showed that LINC02820 overexpression significantly decreased polyubiquitination levels of MYH9 (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6H,I</xref>). Taken together, our results demonstrate that LINC02820 interacts with MYH9 and protects it from ubiquitination&#x02010;mediated proteasomal degradation.</p></sec></sec><sec id="mco270218-sec-0100"><label>3</label><title>Discussion</title><p>ESCC is a highly aggressive malignancy with poor clinical outcomes, underscoring the need to elucidate its molecular mechanisms and identify novel therapeutic targets. Recently, some lncRNAs, such as TMEM44&#x02010;AS1 and LINK&#x02010;A, have been reported to participate in ESCC tumor growth and metastasis [<xref rid="mco270218-bib-0035" ref-type="bibr">35</xref>, <xref rid="mco270218-bib-0036" ref-type="bibr">36</xref>], indicating the important role of lncRNAs in ESCC progression. However, given the vast repertoire of lncRNAs expressed in cells, the functional characterization of dysregulated lncRNAs in ESCC remains largely unexplored. In this study, we employed high&#x02010;throughput RNA&#x02010;sequencing and bioinformatics analysis to identify LINC02820 as one of the most significantly upregulated lncRNAs in ESCC tumors compared with normal tissues (Figure&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1A&#x02013;C</xref>), which was further validated by RT&#x02010;qPCR assays (Figure&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1E</xref>), TCGA dataset (Figure&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1F</xref>), and GSE130078 dataset analysis (Figure&#x000a0;<xref rid="mco270218-fig-0001" ref-type="fig">1G</xref>). These results strongly suggest the potential oncogenic role of LINC02820 in ESCC progression.</p><p>RNA abundance is tightly regulated through both transcriptional and posttranscriptional mechanisms. For example, the transcription factor MYC activates LINC00346 expression by binding to promoter regions, and elevated LINC00346 expression promotes gastric cancer progression [<xref rid="mco270218-bib-0037" ref-type="bibr">37</xref>]. Posttranscriptionally, RBPs may modulate RNA stability through sequence&#x02010;specific interactions. For instance, HuR stabilizes target mRNAs (including c&#x02010;MYC and p21) by recognizing AU&#x02010;rich elements (AREs) in their 3&#x02032; untranslated regions (3&#x02032; UTRs) [<xref rid="mco270218-bib-0038" ref-type="bibr">38</xref>]. Our study identified the association of IGF2BP2 with LINC02820, as evidenced by RNA pull&#x02010;down assays (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5D</xref>) and RBP immunoprecipitation (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5E</xref>). Moreover, IGF2BP2 depletion shorten the half&#x02010;life of LINC02820 (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5G</xref>) and thus decreased steady&#x02010;state LINC02820 levels (Figure&#x000a0;<xref rid="mco270218-fig-0005" ref-type="fig">5H</xref>). Consistent with the previous report [<xref rid="mco270218-bib-0039" ref-type="bibr">39</xref>], we found IGF2BP2 overexpression in ESCC, which may contribute to elevated LINC02820 expression in tumors. While IGF2BP family proteins are reported to recognize &#x0201c;CAUC&#x0201d; or &#x0201c;UGGAC&#x0201d; motifs [<xref rid="mco270218-bib-0040" ref-type="bibr">40</xref>], the specific binding sequence within LINC02820 requires further characterization.</p><p>Although LINC02820 was found to be dysregulated in ESCC [<xref rid="mco270218-bib-0041" ref-type="bibr">41</xref>], its accurate sequence has not been validated. In this study, we employed RACE technologies and Sanger sequencing to experimentally identify the transcription initiation and termination sites of LINC02820 (Figure&#x000a0;<xref rid="mco270218-fig-0002" ref-type="fig">2B,C</xref>). Moreover, the full&#x02010;length of LINC02820 was successfully amplified for sequencing (Figure&#x000a0;<xref rid="mco270218-fig-0002" ref-type="fig">2D</xref>). Our analysis reveals that LINC02820 is located at the 12q21.31 region. Compared with the reference sequence (ENST00000555596 in Ensembl database; NR_183553 in NCBI database), LINC02820 we identified is 695 nucleotides in length, with 16 additional nucleotides at the 5&#x02032;&#x02010;end and 118 additional nucleotides at the 3&#x02032;&#x02010;end (Figure <xref rid="mco270218-supinfo-0001" ref-type="">S2</xref>), indicating that LINC02820 we identified is a novel transcript variant in ESCC.</p><p>To investigate the functional role of LINC02820 in ESCC, we established stable cell lines overexpressing this lncRNA. Functional assays indicated that LINC02820 significantly enhanced both proliferative and migratory capacities of ESCC cells (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3A&#x02013;F</xref>). Conversely, LINC02820 depletion using two independent shRNAs effectively suppressed cell proliferation and migration (Figure&#x000a0;<xref rid="mco270218-fig-0004" ref-type="fig">4</xref>), confirming its oncogenic functions in ESCC cells. These in vitro findings were further corroborated by in vivo studies showing that LINC02820 promoted tumor growth and metastasis in xenograft models (Figure&#x000a0;<xref rid="mco270218-fig-0003" ref-type="fig">3G&#x02013;K</xref>). Interestingly, Wang et&#x000a0;al. [<xref rid="mco270218-bib-0041" ref-type="bibr">41</xref>] reported that LINC02820 primarily promotes cell migration without impacting proliferation. This functional discrepancy may stem from differences between the transcript variant we identified (containing additional 5&#x02032; and 3&#x02032; sequences) and previously reported isoforms, suggesting that distinct LINC02820 transcripts may adopt different conformations to exert specific biological functions.</p><p>Compelling evidence indicates that lncRNAs modulate gene expression through protein interactions at posttranscriptional level. For example, the p53&#x02010;responsive lncRNA GUARDIN acts as a scaffold to promote BRCA1&#x02013;BARD1 heterodimer formation, thereby regulating BRCA1 protein level and genomic stability [<xref rid="mco270218-bib-0030" ref-type="bibr">30</xref>]. Similarly, in papillary thyroid carcinoma, the lncRNA AB074169 interacts with KHSRP protein to downregulate its expression and inhibit cell proliferation [<xref rid="mco270218-bib-0042" ref-type="bibr">42</xref>]. In this study, we identified MYH9 as a LINC02820&#x02010;interacting protein through RNA pull&#x02010;down and mass spectrometry (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6A</xref>), with subsequent validation by immunoblotting assays (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6B</xref>) and coimmunoprecipitation experiments (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6C</xref>). Through gain&#x02010; and loss&#x02010;of&#x02010;function strategies, LINC02820 was proved to positively regulate MYH9 protein abundance (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6D,E</xref>). Moreover, LINC02820 prevents MYH9 from ubiquitination&#x02010;mediated proteasomal degradation (Figure&#x000a0;<xref rid="mco270218-fig-0006" ref-type="fig">6H,I</xref>). However, the underlying molecular mechanisms remain unclear. For instance, which E3 ubiquitin ligase mediates MYH9 degradation in this context? Are additional RBPs involved in the LINC02820&#x02013;MYH9 interaction? MYH9, a cytoskeletal protein critical for cell motility and morphology, exhibits oncogenic properties in various malignancies including liver cancer, colorectal cancer, and prostate cancer [<xref rid="mco270218-bib-0043" ref-type="bibr">43</xref>, <xref rid="mco270218-bib-0044" ref-type="bibr">44</xref>, <xref rid="mco270218-bib-0045" ref-type="bibr">45</xref>]. Recent work by Li et&#x000a0;al. [<xref rid="mco270218-bib-0029" ref-type="bibr">29</xref>] reported that SAMD9 promotes ESCC progression through upregulating MYH9 expression and subsequent activation of GSK3&#x003b2;/&#x003b2;&#x02010;catenin signaling. Our findings reveal an additional layer of MYH9 regulation in ESCC, highlighting the complexity of its expression control in cancer cells.</p><p>In summary, this study characterized a novel LINC02820 transcript variant that is significantly upregulated in ESCC. We demonstrated that IGF2BP2 binds to and stabilizes LINC02820, leading to its increased expression in ESCC cells. Through comprehensive functional studies, we proved&#x000a0;that LINC02820 promotes cell proliferation and migration <italic toggle="yes">in</italic>
<italic toggle="yes">vitro</italic> and accelerates tumor growth and metastasis in vivo. Mechanistically, LINC02820 interacts with MYH9 and protects it from ubiquitination&#x02010;mediated proteasomal degradation. Therefore, our findings reveal the oncogenic role of LINC02820 in ESCC progression and highlight its potential as a therapeutic target.</p></sec><sec id="mco270218-sec-0110"><label>4</label><title>Materials and Methods</title><sec id="mco270218-sec-0120"><label>4.1</label><title>Clinical Samples</title><p>This study was approved by the Ethics Committee of West China Hospital of Sichuan University and written informed consent was obtained from patients. Fresh ESCC tumors and paired adjacent normal tissues were collected from West China Hospital.</p></sec><sec id="mco270218-sec-0130"><label>4.2</label><title>Cell Culture and Construction of Stable Cells</title><p>Human esophageal squamous cells (TE1, Eca109, KYSE30, KYSE150, KYSE410, and KYSE450) and human embryonic kidney HEK293T cells were cultured in DMEM medium (Gibco) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37&#x000b0;C in a humidified 5% CO<sub>2</sub> incubator. To prepare lentivirus, HEK293T cells were cotransfected with the lentiviral plasmid and packaging plasmids psPAX2 and pMD2G. At 48&#x000a0;h after transfection, supernatants containing lentivirus were collected to infect ESCC cells, followed by selection by puromycin to generate stable cells.</p></sec><sec id="mco270218-sec-0140"><label>4.3</label><title>RNA Extraction and RT&#x02010;qPCR</title><p>Total RNAs were isolated using RNAiso Plus reagent (TaKaRa) according to the manufacturer's protocol. RNA integrity was verified prior to library preparation. After depleting ribosomal RNAs with Ribo&#x02010;Zero rRNA Removal Kit, high&#x02010;throughput RNA&#x02010;sequencing was performed by Novogene Technology Co., Ltd. (Beijing, China) to generate 150&#x000a0;bp paired&#x02010;end reads. For gene expression analysis, 1&#x000a0;&#x000b5;g of total RNAs were reverse transcribed using PrimeScript RT Reagent Kit (TaKaRa), followed by RT&#x02010;qPCR using TB Green Premix Ex Taq II (Tli RNase H Plus) (TaKaRa) on a QuantStudio 6 system (Life Technologies). Relative gene expression was calculated using the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method with normalization to endogenous controls. Primer sequences are listed in Table <xref rid="mco270218-supinfo-0001" ref-type="">S6</xref>.</p></sec><sec id="mco270218-sec-0150"><label>4.4</label><title>Transcriptome Sequencing and Bioinformatics Analysis</title><p>RNA&#x02010;seq data from 62 tumor tissues and 22 matched normal tissues of 22 ESCC patients were obtained from our previous study [<xref rid="mco270218-bib-0046" ref-type="bibr">46</xref>]. Raw reads were quality&#x02010;checked with FastQC (v0.11.8) and trimmed using Trimmomatic (v0.36) [<xref rid="mco270218-bib-0047" ref-type="bibr">47</xref>]. Clean reads were aligned to human reference genome (GRCh37.p13) using HISAT2 (v2.1.0) [<xref rid="mco270218-bib-0048" ref-type="bibr">48</xref>]. Transcript assembly and quantification were performed using StringTie (v2.0.4) [<xref rid="mco270218-bib-0049" ref-type="bibr">49</xref>], guided by the GENCODE v19 human gene annotation, and lncRNA&#x02010;specific counts and FPKM values were extracted for expression profiling.</p><p>Differential expression analysis was performed using DESeq2 (v1.32.0) [<xref rid="mco270218-bib-0050" ref-type="bibr">50</xref>] on lncRNAs with average FPKM&#x000a0;&#x02265;&#x000a0;2, identifying 151 transcripts (118 genes) with fold&#x02010;change &#x0003e;2 and adjusted <italic toggle="yes">p</italic> value &#x0003c;0.05. The 118 genes were compared with 2103 dysregulated lncRNA genes from a published ESCC cohort (HRA003107, 93 pairs) [<xref rid="mco270218-bib-0011" ref-type="bibr">11</xref>], which used the same thresholds without expression filtering, to identify overlapping dysregulated lncRNAs.</p></sec><sec id="mco270218-sec-0160"><label>4.5</label><title>RACE Experiments and Plasmid Construction</title><p>The transcription initiation and termination sites of LINC02820 were determined by FirstChoice RLM&#x02010;RACE Kit (Ambion) according to the manufacturer's instructions. The full&#x02010;length LINC02820 transcript was amplified from KYSE410 cDNAs using Phanta Super&#x02010;Fidelity DNA Polymerase (Vazyme) and subsequently cloned into pCDH&#x02013;CMV&#x02013;EF1&#x02013;PURO for expression studies. For gene knockdown experiments, two independent shRNA oligonucleotides targeting either LINC02820 or IGF2BP2 were designed, annealed, and ligated into the vector pLKO.1&#x02010;puro at <italic toggle="yes">Age</italic>I and <italic toggle="yes">Eco</italic>RI sites. All primer and oligonucleotide sequences used in this study are listed in Table <xref rid="mco270218-supinfo-0001" ref-type="">S6</xref>.</p></sec><sec id="mco270218-sec-0170"><label>4.6</label><title>Cell Proliferation Assays</title><p>For colony formation assay, 3000 cells were seeded into each well of six&#x02010;well plate and cultured in complete medium for 14 days, with medium replacement every 3 days. Following incubation, colonies were fixed with 4% paraformaldehyde for 30&#x000a0;min at room temperature and stained with 0.5% crystal violet solution (Beyotime Biotechnology) for visualization. For MTT assays, 800 cells were seeded into each well of 96&#x02010;well plate and cultured at 37&#x000b0;C. At designated time points, 10&#x000a0;&#x000b5;L of MTT solution (5&#x000a0;mg/mL; Sigma&#x02013;Aldrich) were added to each well, followed by incubation for 3&#x000a0;h at 37&#x000b0;C. The resulting formazan crystals were dissolved, and absorbance was measured at 570&#x000a0;nm using a BioTek microplate reader.</p></sec><sec id="mco270218-sec-0180"><label>4.7</label><title>Transwell Migration and Invasion Assays</title><p>Cell migration and invasion capacities were assessed using 8&#x000a0;&#x000b5;m pore Transwell chambers (Falcon). For invasion assays, chambers were precoated with Matrigel (Corning), while migration assays used uncoated chambers. Cells were suspended in serum&#x02010;free DMEM medium containing 5% BSA and seeded into the upper chamber. The lower chamber contained DMEM medium with 10% FBS as chemoattractant. After 24&#x02010;h incubation, nonmigrated/invaded cells were removed from the upper chamber with cotton swabs. Cells on the lower membrane surface were fixed with 4% paraformaldehyde for 30&#x000a0;min, stained with 0.5% crystal violet solution for 30&#x000a0;min, and imaged using an inverted microscope.</p></sec><sec id="mco270218-sec-0190"><label>4.8</label><title>Immunoblotting Assay</title><p>Proteins were extracted from cells with RIPA lysis buffer (Beyotime Biotechnology; cat#P0013B) plus Protease and Phosphatase Inhibitor Cocktails (Bimake), and protein concentrations were determined by the BCA protein assay kit (Beyotime Biotechnology) according to the manufacturer's instructions. Equal amounts of proteins were separated by 10% SDS&#x02010;PAGE and transferred to PVDF membranes (Millipore) using standard protocols. Membranes were blocked with 5% nonfat milk in TBST for 1&#x000a0;h at room temperature, then incubated overnight at 4&#x000b0;C with primary antibodies. After three washes with TBST, membranes were incubated with appropriate secondary antibodies for 1&#x000a0;h at room temperature. Protein bands were visualized using Enhanced Chemiluminescence Reagent (Thermo Fisher Scientific) and imaged with a ChemiDocTM XRS<sup>+</sup> System (Bio&#x02010;Rad). Primary antibodies used in this study were as follows: GAPDH (CST; cat#3683S; 1:5000), Lamin A/C (Abways; cat#CY5222; 1:2000), IGF2BP2 (Proteintech; cat#11601&#x02010;1&#x02010;AP; 1:1000), MYH9 (Abcam; cat#ab55456; 1:1000), HA&#x02010;Tag (CST; cat#3724S; 1:1000).</p></sec><sec id="mco270218-sec-0200"><label>4.9</label><title>Subcellular Fractionation</title><p>Cells (1&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup>) were gently suspended in the hypotonic buffer (5&#x000a0;mM Tris&#x02013;HCl, pH 7.4, 1.5&#x000a0;mM MgCl<sub>2</sub>, 150&#x000a0;mM NaCl, 0.5% NP&#x02010;40) and incubated on ice for 3&#x000a0;min to allow cell membrane disruption. Following centrifugation at 300&#x000d7;<italic toggle="yes">g</italic> for 2&#x000a0;min at 4&#x000b0;C, the resultant supernatant was collected as the cytoplasmic fraction. The nuclear pellet was washed twice with the hypotonic buffer and subsequently suspended in the nuclear extraction buffer. <italic toggle="yes">GAPDH</italic> mRNA and U6 RNA were used as cytoplasmic and nuclear RNAs, respectively. GAPDH and LaminA/C proteins were used as cytoplasmic and nuclear proteins, respectively.</p></sec><sec id="mco270218-sec-0210"><label>4.10</label><title>in vitro Transcription and RNA Pull&#x02010;Down Assay</title><p>DNA templates for in vitro transcription were amplified by PCR and purified by DNA Gel Extraction Kit (BBI). The in vitro transcription was performed by MAXIscript T7/T3 Transcription Kit (Thermo Fisher Scientific; cat#AM1326) and Biotin RNA Labeling Mix (Roche; cat#11685597910) according to the manufacturer's instructions. For RNA pull&#x02010;down assay, 5&#x000a0;&#x000b5;g of biotinylated LINC02820 sense or antisense transcripts were denatured at 65&#x000b0;C for 5&#x000a0;min and then annealed to form appropriate secondary structures. Cells were lysed in the buffer (150&#x000a0;mM NaCl, 20&#x000a0;mM Tris&#x02013;HCl, pH7.5, 0.5&#x000a0;mM EDTA, 0.5% Triton X&#x02010;100, protease and phosphatase inhibitors cocktail, and RNase inhibitors) using a homogenizer, followed by centrifugation at 16,000&#x000d7;<italic toggle="yes">g</italic> for 15&#x000a0;min. The resultant supernatants were incubated with sense or antisense transcripts at 4&#x000b0;C for 4&#x000a0;h, followed by adding 20&#x000a0;&#x000b5;L Streptavidin T1 (Invitrogen, cat#65601) at 4&#x000b0;C for another 2&#x000a0;h. Finally, pull&#x02010;down samples were subjected to downstream analysis. The primers used for in vitro transcription were listed in Table <xref rid="mco270218-supinfo-0001" ref-type="">S6</xref>.</p></sec><sec id="mco270218-sec-0220"><label>4.11</label><title>Immunoprecipitation</title><p>Cells were suspended for 20&#x000a0;min in the ice&#x02010;cold IP buffer (20&#x000a0;mM Tris&#x02013;HCl, pH7.5, 150&#x000a0;mM NaCl, 0.5&#x000a0;mM EDTA, 0.5% Triton X&#x02010;100) supplemented with protease/phosphatase inhibitors and RNase inhibitors, and then lysed by homogenizer. Lysates were cleared by centrifugation at 16,000&#x000d7;<italic toggle="yes">g</italic> for 15&#x000a0;min at 4&#x000b0;C and incubated with indicated primary antibodies or control IgG. Immune complexes were captured using 20&#x000a0;&#x000b5;L protein A/G agarose (Millipore; cat#IP05) with rotation at 4&#x000b0;C for another 1&#x000a0;h. After washing three times with IP buffer, the immunoprecipitated proteins and RNAs were subjected to Western blot analyses and RT&#x02010;qPCR, respectively.</p></sec><sec id="mco270218-sec-0230"><label>4.12</label><title>Mass Spectrometry and Data Analysis</title><p>Proteins were resolved by 10% SDS&#x02010;PAGE and stained by Coomassie brilliant blue G&#x02010;250 (Sigma). The proteins of interest were excised, destained with 40% acetonitrile/50&#x000a0;mM NH&#x02084;HCO&#x02083;, and then dehydrated in acetonitrile. Subsequently, samples were subjected to reduction by 25&#x000a0;mM NH&#x02084;HCO&#x02083; containing 10&#x000a0;mM DTT and alkylation by 25&#x000a0;mM NH&#x02084;HCO&#x02083; containing 40&#x000a0;mM iodoacetamide, followed by digestion using 5&#x000a0;ng/mL of trypsin in 25&#x000a0;mM NH&#x02084;HCO&#x02083; at 37&#x000b0;C for 16&#x000a0;h. Then, the digestion was terminated with 0.01% formic acid. Finally, peptides were lyophilized using vacuum freeze dryer, desalted using C18 ZipTips (Millipore), and analyzed by LC&#x02013;MS/MS on an Easy&#x02010;nLC 2000 HPLC system coupled to an Orbitrap ExplorisTM 480 mass spectrometer (Thermo Fisher Scientific, USA).</p></sec><sec id="mco270218-sec-0240"><label>4.13</label><title>RNA and Protein Stability Assays</title><p>To measure RNA stability, cells were treated with 10&#x000a0;&#x000b5;M actinomycin D (MedChemExpress; cat#HY&#x02010;17559) to inhibit transcription. Total RNAs were extracted at indicated time points and analyzed by RT&#x02010;qPCR to determine LINC20820 half&#x02010;life. To measure protein stability, cells were treated with 50&#x000a0;&#x000b5;M CHX (Sigma&#x02013;Aldrich; cat#5087390001) to block new protein synthesis. MYH9 protein levels were analyzed by Western blot at indicated time points.</p></sec><sec id="mco270218-sec-0250"><label>4.14</label><title>Animal Experiments</title><p>All mouse procedures were approved by the Institutional Animal Care and Use Committee of West China Hospital, Sichuan University. Nude mice were purchased from Beijing HuaFuKang Bioscience. For xenograft model, 1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells suspended in 100&#x000a0;&#x000b5;L PBS were subcutaneously injected into 5&#x02010;week&#x02010;old male Balb/C athymic nude mice, and tumor volumes were measured and calculated using the formula (length&#x000a0;&#x000d7;&#x000a0;width<sup>2</sup>)/2. For lung metastasis model, 1&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> luciferase&#x02010;labeled cells were injected into tail veins of 6&#x02010;week&#x02010;old male Balb/C athymic nude mice. Five weeks later, tumor metastasis was visualized by IVIS Spectrum system (PerkinElmer) after intraperitoneal injection of <sc>d</sc>&#x02010;luciferin. Bioluminescence intensity was quantified to reflect tumor metastasis of tumor&#x02010;bearing mice.</p></sec><sec id="mco270218-sec-0260"><label>4.15</label><title>Gene Set Enrichment Analysis</title><p>GSEA was performed by the JAVA program (Version 4.2.3) with Molecular Signatures Database (MSigDB) v6.1 to investigate LINC02820&#x02010;associated pathways. The TCGA_ESCA cohort of patients were stratified into high&#x02010; and low&#x02010;LINC02820 groups based on median expression levels. Analysis was conducted using the c2.cp.kegg_legacy.v2023.2.Hs.symbols.gmt gene set from MSigDB as the reference. Significantly enriched pathways were identified based on the highest Enrichment Score (ES) with a normalized <italic toggle="yes">p</italic> value &#x0003c;0.05 and a false discovery rate&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec><sec id="mco270218-sec-0270"><label>4.16</label><title>Statistical Analysis</title><p>Statistical analyses were performed using GraphPad Prism software (version 9.0) to assess the differences between experimental groups. Data are presented as the mean&#x000a0;&#x000b1;&#x000a0;standard error of the mean. Statistical significance was determined using two&#x02010;tailed Student's <italic toggle="yes">t</italic>&#x02010;tests (for comparisons between two groups). Significance thresholds were defined as follows: *<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.05; **<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.01; ***<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001.</p></sec></sec><sec id="mco270218-sec-0280"><title>Author Contributions</title><p>Y. P. and Y. D. L. supervised this project and revised the manuscript. X. X. and X. M. performed experiments and wrote the manuscript. W. L. and Y. Y. performed bioinformatics analysis. Y. M. contributed to animal experiments. T. Z. conducted mass spectrometric analysis. A&#x02010;Lai Gu&#x02010;Ha collected clinical samples. All authors have read and approved the final manuscript.</p></sec><sec id="mco270218-sec-0300"><title>Ethics Statements</title><p>This study was approved by the Institutional Animal Care and Use Committee of West China Hospital, Sichuan University (20220614004) and the Clinical Experimental and Biomedical Ethics Committee of West China Hospital, Sichuan University (2019&#x02010;537).</p></sec><sec sec-type="COI-statement" id="mco270218-sec-0310"><title>Conflicts of Interest</title><p>The author Yong Peng is an editorial board member of <italic toggle="yes">MedComm</italic> but was not involved in the journal's review of or decisions related to this manuscript. All authors declared no conflict of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="mco270218-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="mco270218-supitem-0001" position="float" content-type="local-data"><caption><p>Supporting Information</p></caption><media xlink:href="MCO2-6-e70218-s002.pdf"/></supplementary-material><supplementary-material id="mco270218-supitem-0002" position="float" content-type="local-data"><caption><p>Supporting Information</p></caption><media xlink:href="MCO2-6-e70218-s001.xlsx"/></supplementary-material></sec></body><back><ack id="mco270218-sec-0290"><title>Acknowledgments</title><p>This work was supported by the 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University (ZYGD23027). The Graphic Abstract figure of this article is created with BioRender.com.</p></ack><sec sec-type="data-availability" id="mco270218-sec-0330"><title>Data Availability Statement</title><p>The data included in this study are available upon request from the corresponding author.</p></sec><ref-list id="mco270218-bibl-0001"><title>References</title><ref id="mco270218-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="mco270218-cite-0001">
<string-name>
<given-names>M.</given-names>
<surname>di Pietro</surname>
</string-name>, <string-name>
<given-names>M. I.</given-names>
<surname>Canto</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>RC</surname>
</string-name>, &#x0201c;<article-title>Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy</article-title>,&#x0201d; <source>Gastroenterology</source>
<volume>154</volume>, no. <issue>2</issue> (<year>2018</year>): <fpage>421</fpage>&#x02013;<lpage>436</lpage>.<pub-id pub-id-type="pmid">28778650</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="mco270218-cite-0002">
<string-name>
<given-names>E. C.</given-names>
<surname>Smyth</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Lagergren</surname>
</string-name>, <string-name>
<given-names>R. C.</given-names>
<surname>Fitzgerald</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Oesophageal Cancer</article-title>,&#x0201d; <source>Nature reviews Disease Primers</source>
<volume>3</volume> (<year>2017</year>): <elocation-id>17048</elocation-id>.</mixed-citation></ref><ref id="mco270218-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="mco270218-cite-0003">
<string-name>
<given-names>K. D.</given-names>
<surname>Miller</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Nogueira</surname>
</string-name>, <string-name>
<given-names>A. B.</given-names>
<surname>Mariotto</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cancer Treatment and Survivorship Statistics, 2019</article-title>,&#x0201d; <source>CA: A Cancer Journal for Clinicians</source>
<volume>69</volume>, no. <issue>5</issue> (<year>2019</year>): <fpage>363</fpage>&#x02013;<lpage>385</lpage>.<pub-id pub-id-type="pmid">31184787</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="mco270218-cite-0004">
<string-name>
<given-names>A. M.</given-names>
<surname>Schmitt</surname>
</string-name> and <string-name>
<given-names>H. Y.</given-names>
<surname>Chang</surname>
</string-name>, &#x0201c;<article-title>Long Noncoding RNAs in Cancer Pathways</article-title>,&#x0201d; <source>Cancer Cell</source>
<volume>29</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>452</fpage>&#x02013;<lpage>463</lpage>.<pub-id pub-id-type="pmid">27070700</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="mco270218-cite-0005">
<string-name>
<given-names>S.</given-names>
<surname>Adnane</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Marino</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Leucci</surname>
</string-name>, &#x0201c;<article-title>LncRNAs in human Cancers: Signal From Noise</article-title>,&#x0201d; <source>Trends in Cell Biology</source>
<volume>32</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>565</fpage>&#x02013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">35168846</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="mco270218-cite-0006">
<string-name>
<given-names>F.</given-names>
<surname>Kopp</surname>
</string-name> and <string-name>
<given-names>J. T.</given-names>
<surname>Mendell</surname>
</string-name>, &#x0201c;<article-title>Functional Classification and Experimental Dissection of Long Noncoding RNAs</article-title>,&#x0201d; <source>Cell</source>
<volume>172</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>393</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">29373828</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="mco270218-cite-0007">
<string-name>
<given-names>H.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Zhang</surname>
</string-name>, and <string-name>
<given-names>H. M.</given-names>
<surname>Krause</surname>
</string-name>, &#x0201c;<article-title>Long Noncoding RNAs and Repetitive Elements: Junk or Intimate Evolutionary Partners?</article-title>,&#x0201d; <source>Trends in Genetics</source>
<volume>35</volume>, no. <issue>12</issue> (<year>2019</year>): <fpage>892</fpage>&#x02013;<lpage>902</lpage>.<pub-id pub-id-type="pmid">31662190</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="mco270218-cite-0008">
<string-name>
<given-names>Q.</given-names>
<surname>Feng</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Yao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Emerging Role of Non&#x02010;coding RNAs in Esophageal Squamous Cell Carcinoma</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>21</volume>, no. <issue>1</issue> (<year>2019</year>).</mixed-citation></ref><ref id="mco270218-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="mco270218-cite-0009">
<string-name>
<given-names>Y.</given-names>
<surname>Hosono</surname>
</string-name>, <string-name>
<given-names>Y. S.</given-names>
<surname>Niknafs</surname>
</string-name>, <string-name>
<given-names>J. R.</given-names>
<surname>Prensner</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non&#x02010;coding RNA</article-title>,&#x0201d; <source>Cell</source>
<volume>171</volume>, no. <issue>7</issue> (<year>2017</year>): <fpage>1559</fpage>&#x02013;<lpage>1572</lpage>. e1520.<pub-id pub-id-type="pmid">29245011</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="mco270218-cite-0010">
<string-name>
<given-names>M.</given-names>
<surname>Luo</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long Non&#x02010;coding RNA H19 Increases Bladder Cancer Metastasis by Associating With EZH2 and Inhibiting E&#x02010;cadherin Expression</article-title>,&#x0201d; <source>Cancer Letters</source>
<volume>333</volume>, no. <issue>2</issue> (<year>2013</year>): <fpage>213</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">23354591</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="mco270218-cite-0011">
<string-name>
<given-names>M.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bao</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Gong</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Transcriptional Landscape and Diagnostic Potential of Long Non&#x02010;coding RNAs in Esophageal Squamous Cell Carcinoma</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>14</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>3799</fpage>.</mixed-citation></ref><ref id="mco270218-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="mco270218-cite-0012">
<string-name>
<given-names>J. J.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>Y. Y.</given-names>
<surname>Jiang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Jiang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Super&#x02010;enhancer&#x02010;driven Long Non&#x02010;coding RNA LINC01503, Regulated by TP63, Is Over&#x02010;expressed and Oncogenic in Squamous Cell Carcinoma</article-title>,&#x0201d; <source>Gastroenterology</source>
<volume>154</volume>, no. <issue>8</issue> (<year>2018</year>): <fpage>2137</fpage>&#x02013;<lpage>2151</lpage>. e2131.<pub-id pub-id-type="pmid">29454790</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="mco270218-cite-0013">
<string-name>
<given-names>S. T.</given-names>
<surname>Xue</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>S. Q.</given-names>
<surname>Cao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long Non&#x02010;coding RNA LINC00680 Functions as a ceRNA to Promote Esophageal Squamous Cell Carcinoma Progression Through the miR&#x02010;423&#x02010;5p/PAK6 Axis</article-title>,&#x0201d; <source>Molecular Cancer</source>
<volume>21</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>69</fpage>.<pub-id pub-id-type="pmid">35255921</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="mco270218-cite-0014">
<string-name>
<given-names>Y.</given-names>
<surname>Cui</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ma</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>RNA m6A Demethylase FTO&#x02010;mediated Epigenetic Up&#x02010;regulation of LINC00022 Promotes Tumorigenesis in Esophageal Squamous Cell Carcinoma</article-title>,&#x0201d; <source>Journal of Experimental &#x00026; Clinical Cancer Research</source>
<volume>40</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>294</fpage>.<pub-id pub-id-type="pmid">34544449</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="mco270218-cite-0015">
<string-name>
<given-names>Y.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Fang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Lipid Metabolism&#x02010;related lncRNA SLC25A21&#x02010;AS1 Promotes the Progression of Oesophageal Squamous Cell Carcinoma by Regulating the NPM1/c&#x02010;Myc Axis and SLC25A21 Expression</article-title>,&#x0201d; <source>Clinical and Translational Medicine</source>
<volume>12</volume>, no. <issue>6</issue> (<year>2022</year>): <elocation-id>e944</elocation-id>.<pub-id pub-id-type="pmid">35735113</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="mco270218-cite-0016">
<string-name>
<given-names>Y.</given-names>
<surname>Jia</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Tian</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long Non&#x02010;coding RNA NORAD/miR&#x02010;224&#x02010;3p/MTDH Axis Contributes to CDDP Resistance of Esophageal Squamous Cell Carcinoma by Promoting Nuclear Accumulation of &#x003b2;&#x02010;catenin</article-title>,&#x0201d; <source>Molecular Cancer</source>
<volume>20</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>162</fpage>.<pub-id pub-id-type="pmid">34893064</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="mco270218-cite-0017">
<string-name>
<given-names>J.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Z. X.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Q. N.</given-names>
<surname>Wu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long Noncoding RNA AGPG Regulates PFKFB3&#x02010;mediated Tumor Glycolytic Reprogramming</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>1507</fpage>.</mixed-citation></ref><ref id="mco270218-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="mco270218-cite-0018">
<string-name>
<given-names>K.</given-names>
<surname>Nemeth</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Bayraktar</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ferracin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Non&#x02010;coding RNAs in Disease: From Mechanisms to Therapeutics</article-title>,&#x0201d; <source>Nature Reviews Genetics</source>
<volume>25</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>211</fpage>&#x02013;<lpage>232</lpage>.</mixed-citation></ref><ref id="mco270218-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="mco270218-cite-0019">
<string-name>
<given-names>T.</given-names>
<surname>Mondal</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Subhash</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Vaid</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MEG3 long Noncoding RNA Regulates the TGF&#x02010;&#x003b2; Pathway Genes Through Formation of RNA&#x02010;DNA Triplex Structures</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>6</volume> (<year>2015</year>): <fpage>7743</fpage>.</mixed-citation></ref><ref id="mco270218-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="mco270218-cite-0020">
<string-name>
<given-names>A.</given-names>
<surname>Keniry</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Oxley</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Monnier</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The H19 lincRNA Is a Developmental Reservoir of miR&#x02010;675 That Suppresses Growth and Igf1r</article-title>,&#x0201d; <source>Nature Cell Biology</source>
<volume>14</volume>, no. <issue>7</issue> (<year>2012</year>): <fpage>659</fpage>&#x02013;<lpage>665</lpage>.<pub-id pub-id-type="pmid">22684254</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="mco270218-cite-0021">
<string-name>
<given-names>M.</given-names>
<surname>Huarte</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Guttman</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Feldser</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response</article-title>,&#x0201d; <source>Cell</source>
<volume>142</volume>, no. <issue>3</issue> (<year>2010</year>): <fpage>409</fpage>&#x02013;<lpage>419</lpage>.<pub-id pub-id-type="pmid">20673990</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="mco270218-cite-0022">
<string-name>
<given-names>Z.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Y. X.</given-names>
<surname>Lu</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>lncRNA BREA2 Promotes Metastasis by Disrupting the WWP2&#x02010;mediated Ubiquitination of Notch1</article-title>,&#x0201d; <source>PNAS</source>
<volume>120</volume>, no. <issue>8</issue> (<year>2023</year>): <elocation-id>e2206694120</elocation-id>.<pub-id pub-id-type="pmid">36795754</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="mco270218-cite-0023">
<string-name>
<given-names>Y. P.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>Y. P.</given-names>
<surname>Jin</surname>
</string-name>, <string-name>
<given-names>X. S.</given-names>
<surname>Wu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>LncRNA&#x02010;HGBC Stabilized by HuR Promotes Gallbladder Cancer Progression by Regulating miR&#x02010;502&#x02010;3p/SET/AKT Axis</article-title>,&#x0201d; <source>Molecular cancer</source>
<volume>18</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>167</fpage>.<pub-id pub-id-type="pmid">31752906</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="mco270218-cite-0024">
<string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Qiang</surname>
</string-name>, &#x0201c;<article-title>The Role of IGF2BP2, an m6A Reader Gene, in human Metabolic Diseases and Cancers</article-title>,&#x0201d; <source>Cancer cell international</source>
<volume>21</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>99</fpage>.<pub-id pub-id-type="pmid">33568150</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="mco270218-cite-0025">
<string-name>
<given-names>Y.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Deng</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>CSTF2 mediated mRNA N(6)&#x02010;methyladenosine Modification Drives Pancreatic Ductal Adenocarcinoma M(6)A Subtypes</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>14</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>6334</fpage>.</mixed-citation></ref><ref id="mco270218-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="mco270218-cite-0026">
<string-name>
<given-names>X.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>W. X.</given-names>
<surname>Peng</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhou</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>IGF2BP2 regulates DANCR by Serving as an N6&#x02010;methyladenosine Reader</article-title>,&#x0201d; <source>Cell Death and Differentiation</source>
<volume>27</volume>, no. <issue>6</issue> (<year>2020</year>): <fpage>1782</fpage>&#x02013;<lpage>1794</lpage>.<pub-id pub-id-type="pmid">31804607</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="mco270218-cite-0027">
<string-name>
<given-names>T.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Tang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>IGF2BP2 enhances LincRNA01116 Stability via M(6) A: A Potential Biomarker and Therapeutic Target for Patients With Pre&#x02010;eclampsia</article-title>,&#x0201d; <source>Journal of Cellular Biochemistry</source>
<volume>124</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>239</fpage>&#x02013;<lpage>253</lpage>.<pub-id pub-id-type="pmid">36538649</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="mco270218-cite-0028">
<string-name>
<given-names>Q.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Cheng</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Huang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MYH9: A Key Protein Involved in Tumor Progression and Virus&#x02010;related Diseases</article-title>,&#x0201d; <source>Biomedicine &#x00026; Pharmacotherapy</source>
<volume>171</volume> (<year>2024</year>): <elocation-id>116118</elocation-id>.<pub-id pub-id-type="pmid">38181716</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="mco270218-cite-0029">
<string-name>
<given-names>Q.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Luo</surname>
</string-name>, <string-name>
<given-names>F. Q.</given-names>
<surname>Dai</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>SAMD9 promotes Postoperative Recurrence of Esophageal Squamous Cell Carcinoma by Stimulating MYH9&#x02010;mediated GSK3&#x003b2;/&#x003b2;&#x02010;catenin Signaling</article-title>,&#x0201d; <source>Adv Sci (Weinh)</source>
<volume>10</volume>, no. <issue>11</issue> (<year>2023</year>): <elocation-id>e2203573</elocation-id>.<pub-id pub-id-type="pmid">36757050</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="mco270218-cite-0030">
<string-name>
<given-names>W. L.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Jin</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Xu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>GUARDIN Is a p53&#x02010;responsive Long Non&#x02010;coding RNA That Is Essential for Genomic Stability</article-title>,&#x0201d; <source>Nature Cell Biology</source>
<volume>20</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>492</fpage>&#x02013;<lpage>502</lpage>.<pub-id pub-id-type="pmid">29593331</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="mco270218-cite-0031">
<string-name>
<given-names>X.</given-names>
<surname>Ren</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Deng</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long Noncoding RNA TPRG1&#x02010;AS1 Suppresses Migration of Vascular Smooth Muscle Cells and Attenuates Atherogenesis via Interacting With MYH9 Protein</article-title>,&#x0201d; <source>Arteriosclerosis, Thrombosis, and Vascular Biology</source>
<volume>42</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>1378</fpage>&#x02013;<lpage>1397</lpage>.<pub-id pub-id-type="pmid">36172865</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="mco270218-cite-0032">
<string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Su</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>circ&#x02010;EIF6 Encodes EIF6&#x02010;224aa to Promote TNBC Progression via Stabilizing MYH9 and Activating the Wnt/Beta&#x02010;catenin Pathway</article-title>,&#x0201d; <source>Molecular Therapy</source>
<volume>30</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>415</fpage>&#x02013;<lpage>430</lpage>.<pub-id pub-id-type="pmid">34450253</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="mco270218-cite-0033">
<string-name>
<given-names>Q.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Feng</surname>
</string-name>, <string-name>
<given-names>X. H.</given-names>
<surname>Zhu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>DNAJA4 suppresses Epithelial&#x02010;mesenchymal Transition and Metastasis in Nasopharyngeal Carcinoma via PSMD2&#x02010;mediated MYH9 Degradation</article-title>,&#x0201d; <source>Cell death &#x00026; disease</source>
<volume>14</volume>, no. <issue>10</issue> (<year>2023</year>): <fpage>697</fpage>.<pub-id pub-id-type="pmid">37875476</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="mco270218-cite-0034">
<string-name>
<given-names>K. N.</given-names>
<surname>Swatek</surname>
</string-name> and <string-name>
<given-names>D.</given-names>
<surname>Komander</surname>
</string-name>, &#x0201c;<article-title>Ubiquitin Modifications</article-title>,&#x0201d; <source>Cell Research</source>
<volume>26</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>399</fpage>&#x02013;<lpage>422</lpage>.<pub-id pub-id-type="pmid">27012465</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="mco270218-cite-0035">
<string-name>
<given-names>R.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wan</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ma</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>TMEM44&#x02010;AS1 promotes Esophageal Squamous Cell Carcinoma Progression by Regulating the IGF2BP2&#x02010;GPX4 Axis in Modulating Ferroptosis</article-title>,&#x0201d; <source>Cell Death Discov</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>431</fpage>.<pub-id pub-id-type="pmid">38040698</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="mco270218-cite-0036">
<string-name>
<given-names>Y.</given-names>
<surname>Nan</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Luo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>m(6)A Demethylase FTO Stabilizes LINK&#x02010;A to Exert Oncogenic Roles via MCM3&#x02010;mediated Cell&#x02010;cycle Progression and HIF&#x02010;1&#x003b1; Activation</article-title>,&#x0201d; <source>Cell reports</source>
<volume>42</volume>, no. <issue>10</issue> (<year>2023</year>): <elocation-id>113273</elocation-id>.<pub-id pub-id-type="pmid">37858471</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="mco270218-cite-0037">
<string-name>
<given-names>T. P.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>W. Y.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>KLF5 and MYC Modulated LINC00346 Contributes to Gastric Cancer Progression Through Acting as a Competing Endogeous RNA and Indicates Poor Outcome</article-title>,&#x0201d; <source>Cell Death and Differentiation</source>
<volume>26</volume>, no. <issue>11</issue> (<year>2019</year>): <fpage>2179</fpage>&#x02013;<lpage>2193</lpage>.<pub-id pub-id-type="pmid">30770877</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="mco270218-cite-0038">
<string-name>
<given-names>C. M.</given-names>
<surname>Brennan</surname>
</string-name> and <string-name>
<given-names>J. A.</given-names>
<surname>Steitz</surname>
</string-name>, &#x0201c;<article-title>HuR and mRNA Stability</article-title>,&#x0201d; <source>Cellular and Molecular Life Sciences</source>
<volume>58</volume>, no. <issue>2</issue> (<year>2001</year>): <fpage>266</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">11289308</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="mco270218-cite-0039">
<string-name>
<given-names>C.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Zhu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>IGF2BP2&#x02010;induced circRUNX1 Facilitates the Growth and Metastasis of Esophageal Squamous Cell Carcinoma Through miR&#x02010;449b&#x02010;5p/FOXP3 Axis</article-title>,&#x0201d; <source>Journal of Experimental &#x00026; Clinical Cancer Research</source>
<volume>41</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>347</fpage>.<pub-id pub-id-type="pmid">36522683</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="mco270218-cite-0040">
<string-name>
<given-names>H.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Weng</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Sun</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Recognition of RNA N&#x02010;methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation</article-title>,&#x0201d; <source>Nature Cell Biology</source>
<volume>20</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>285</fpage>&#x02013;<lpage>295</lpage>.<pub-id pub-id-type="pmid">29476152</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="mco270218-cite-0041">
<string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Mei</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Novel Long Noncoding RNA LINC02820 Augments TNF Signaling Pathway to Remodel Cytoskeleton and Potentiate Metastasis in Esophageal Squamous Cell Carcinoma</article-title>,&#x0201d; <source>Cancer Gene Therapy</source>
<volume>30</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>375</fpage>&#x02013;<lpage>387</lpage>.<pub-id pub-id-type="pmid">36357564</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="mco270218-cite-0042">
<string-name>
<given-names>Q.</given-names>
<surname>Gou</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Nie</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long Noncoding RNA AB074169 Inhibits Cell Proliferation via Modulation of KHSRP&#x02010;mediated CDKN1a Expression in Papillary Thyroid Carcinoma</article-title>,&#x0201d; <source>Cancer Research</source>
<volume>78</volume>, no. <issue>15</issue> (<year>2018</year>): <fpage>4163</fpage>&#x02013;<lpage>4174</lpage>.<pub-id pub-id-type="pmid">29735546</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="mco270218-cite-0043">
<string-name>
<given-names>X.</given-names>
<surname>Lin</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Y. H.</given-names>
<surname>Li</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Silencing MYH9 Blocks HBx&#x02010;induced GSK3&#x003b2; Ubiquitination and Degradation to Inhibit Tumor Stemness in Hepatocellular Carcinoma</article-title>,&#x0201d; <source>Signal Transduct Target Ther</source>
<volume>5</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>13</fpage>.<pub-id pub-id-type="pmid">32296025</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="mco270218-cite-0044">
<string-name>
<given-names>Y.</given-names>
<surname>Zhong</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Long</surname>
</string-name>, <string-name>
<given-names>C. S.</given-names>
<surname>Gu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MYH9&#x02010;dependent Polarization of ATG9B Promotes Colorectal Cancer Metastasis by Accelerating Focal Adhesion Assembly</article-title>,&#x0201d; <source>Cell Death and Differentiation</source>
<volume>28</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>3251</fpage>&#x02013;<lpage>3269</lpage>.<pub-id pub-id-type="pmid">34131310</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="mco270218-cite-0045">
<string-name>
<given-names>S.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Zhao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>TUBB4A interacts With MYH9 to Protect the Nucleus During Cell Migration and Promotes Prostate Cancer via GSK3&#x003b2;/&#x003b2;&#x02010;catenin Signalling</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>13</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>2792</fpage>.</mixed-citation></ref><ref id="mco270218-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="mco270218-cite-0046">
<string-name>
<given-names>C.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>W. R.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Tan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Characterization of Distinct Circular RNA Signatures in Solid Tumors</article-title>,&#x0201d; <source>Molecular cancer</source>
<volume>21</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>63</fpage>.<pub-id pub-id-type="pmid">35236349</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="mco270218-cite-0047">
<string-name>
<given-names>A. M.</given-names>
<surname>Bolger</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lohse</surname>
</string-name>, and <string-name>
<given-names>B.</given-names>
<surname>Usadel</surname>
</string-name>, &#x0201c;<article-title>Trimmomatic: A Flexible Trimmer for Illumina Sequence Data</article-title>,&#x0201d; <source>Bioinformatics</source>
<volume>30</volume>, no. <issue>15</issue> (<year>2014</year>): <fpage>2114</fpage>&#x02013;<lpage>2120</lpage>.<pub-id pub-id-type="pmid">24695404</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="mco270218-cite-0048">
<string-name>
<given-names>D.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Langmead</surname>
</string-name>, and <string-name>
<given-names>S. L.</given-names>
<surname>Salzberg</surname>
</string-name>, &#x0201c;<article-title>HISAT: A Fast Spliced Aligner With Low Memory Requirements</article-title>,&#x0201d; <source>Nature Methods</source>
<volume>12</volume>, no. <issue>4</issue> (<year>2015</year>): <fpage>357</fpage>&#x02013;<lpage>360</lpage>.<pub-id pub-id-type="pmid">25751142</pub-id>
</mixed-citation></ref><ref id="mco270218-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="mco270218-cite-0049">
<string-name>
<given-names>M.</given-names>
<surname>Pertea</surname>
</string-name>, <string-name>
<given-names>G. M.</given-names>
<surname>Pertea</surname>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Antonescu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>StringTie Enables Improved Reconstruction of a Transcriptome From RNA&#x02010;seq Reads</article-title>,&#x0201d; <source>Nature Biotechnology</source>
<volume>33</volume>, no. <issue>3</issue> (<year>2015</year>): <fpage>290</fpage>&#x02013;<lpage>295</lpage>.</mixed-citation></ref><ref id="mco270218-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="mco270218-cite-0050">
<string-name>
<given-names>M. I.</given-names>
<surname>Love</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Huber</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Anders</surname>
</string-name>, &#x0201c;<article-title>Moderated Estimation of Fold Change and Dispersion for RNA&#x02010;seq Data With DESeq2</article-title>,&#x0201d; <source>Genome biology</source>
<volume>15</volume>, no. <issue>12</issue> (<year>2014</year>): <fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation></ref></ref-list></back></article>